Scholars@Duke
David Blaine Ridley

David Blaine Ridley

Professor of the Practice of Business Administration
Fuqua School of Business
david.ridley@duke.edu
Duke Box 90120, 100 Fuqua Drive, Durham, NC 27708-0120
100 Fuqua Drive, Durham, NC 27708-0120

Scholarly Works - Journal articles

European priority review vouchers for neglected disease product development.

Journal article BMJ global health · January 2024 IntroductionNeglected diseases are a significant global health challenge. Encouraging the development of therapeutics and vaccines for these diseases would address an important unmet medical need. We propose a priority review voucher programme for ... Full text Cite

Consequences of a shortage and rationing: Evidence from a pediatric vaccine.

Journal article Journal of health economics · December 2023 Shortages and rationing are common in health care, yet we know little about the consequences. We examine an 18-month shortage of the pediatric Haemophilus Influenzae Type B (Hib) vaccine. Using insurance claims data and variation in shortage exposure acros ... Full text Cite

FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels.

Journal article Health affairs (Project Hope) · December 2023 During the initial phase of the COVID-19 pandemic, the Food and Drug Administration (FDA) halted inspections of most overseas drug manufacturing establishments. Looking at data from the period 2012-22, we observed steep declines in both foreign and domesti ... Full text Cite

​US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access.

Journal article Health affairs (Project Hope) · August 2021 The COVID-19 global pandemic has devastated lives and economies. It has served as a reminder of how critical it is to invest in preventing and treating infectious diseases. Until the COVID-19 pandemic, the largest US government-sponsored reward for infecti ... Full text Cite

Does medicare reimbursement drive up drug launch prices?

Journal article Review of Economics and Statistics · December 1, 2020 Featured Publication Medicare reimburses health care providers for the drugs they administer. Since 2005, it has reimbursed based on the past price of the drug. Reimbursement on past prices could motivate manufacturers to set higher launch prices because providers become less ... Full text Cite

Strategic interaction among governments in the provision of a global public good

Journal article Journal of Public Economics · December 1, 2017 Featured Publication How do governments respond to other governments when providing a global public good? Using data from 2007 to 2014 on medical research funding for infectious and parasitic diseases, we examine how governments and foundations in 41 countries respond to fundi ... Full text Open Access Cite

A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases.

Journal article Health affairs (Project Hope) · August 2017 Featured Publication Many in the scientific community are concerned about the potential increase in prevalence of insect-borne diseases such as Chagas disease, Chikungunya, dengue fever, malaria, and Zika in the United States and around the world. Beyond vaccines and drugs to ... Full text Cite

The role of government reimbursement in drug shortages

Journal article American Economic Journal Economic Policy · May 1, 2017 Featured Publication Beginning in the mid- 2000s, the incidence of drug shortages rose, especially for generic injectable drugs such as anesthetics and chemotherapy treatments. We examine whether reimbursement changes contributed to the shortages, focusing on a reduction in Me ... Full text Open Access Cite

Priorities for the Priority Review Voucher.

Journal article The American journal of tropical medicine and hygiene · January 2017 The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food a ... Full text Open Access Cite

Regulation of price increases

Journal article International Journal of Industrial Organization · January 1, 2017 Featured Publication U.S. federal and state governments rarely regulate healthcare price levels, but do regulate price changes for pharmaceuticals, hospitals, and health insurance. Previous research showed that limiting price increases can raise launch prices and reduce both p ... Full text Cite

Real-World Data: Policy Issues Regarding their Access and Use.

Journal article Medical care · December 2016 As real-world data (RWD) in health care begin to cross over to the Big Data realms, a panel of health economists was gathered to establish how well the current US policy environment further the goals of RWD and, if not, what can be done to improve matters. ... Full text Cite

Real-World Data: Responses to Zito and Doshi.

Journal article Medical care · December 2016 Full text Cite

Regulation of Price Increases

Journal article · August 22, 2016 Cite

The Commercial Market For Priority Review Vouchers.

Journal article Health affairs (Project Hope) · May 2016 Featured Publication In 2007 the US Congress created the priority review voucher program to encourage the development of drugs for neglected diseases. Under the program, the developer of a drug that treats a neglected disease receives both a faster review of the drug by the Fo ... Full text Cite

Efficacy of the Priority Review Voucher Program.

Journal article JAMA · April 2016 Featured Publication Full text Cite

No Shot: US Vaccine Prices And Shortages.

Journal article Health affairs (Project Hope) · February 2016 In 2004 an Institute of Medicine report warned of vaccine shortages, raising concerns about disease outbreaks. More than a decade later, we looked for progress in reducing vaccine shortages. We analyzed data on vaccine sales and shortages reported by pract ... Full text Cite

Market watch: Forecasting market share in the US pharmaceutical market.

Journal article Nature reviews. Drug discovery · September 2015 Featured Publication Full text Cite

Forecasting Market Share in the US Pharmaceutical Market

Journal article Nature Reviews Drug Discovery. 2015. · July 31, 2015 Featured Publication Cite

Pharmaceutical followers

Journal article International Journal of Industrial Organization · November 15, 2013 Featured Publication We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer drugs from 1991 to 2010. Our simulations show that gen ... Full text Cite

Pharmaceutical Followers

Journal article · October 2013 Cite

Innovation incentives under transferable fast-track regulatory review

Journal article Journal of Industrial Economics · September 1, 2013 Featured Publication Under a 2007 U.S. law, the developer of a treatment for a neglected disease is rewarded with a fast-track voucher that can be sold to another developer. Similar fast-track vouchers are being offered by other agencies. We model how the existence of transfer ... Full text Cite

Payments, promotion, and the purple pill

Journal article Health Economics (United Kingdom) · 2013 Featured Publication Understanding competition in the US drug market requires knowing how sensitive demand is to prices. The relevant prices for insured consumers are copayments. There are many studies of copayment elasticity in the health literature, but they are of limited a ... Full text Cite

Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.

Journal article Lancet · September 11, 2010 Featured Publication Every year 1 billion people worldwide are affected by traditionally neglected diseases, such as malaria, tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public health burdens. Governments, foundations, and drug manufacturers ... Full text Link to item Cite

Distance decreases with differentiation: Strategic agglomeration by retailers

Journal article International Journal of Industrial Organization · May 1, 2009 Theory predicts intense price competition results when firms cluster with rivals. Yet, strong evidence of clustering is found in previous empirical research. Researchers typically measure clustering by comparing observed location patterns to random assignm ... Full text Cite

FDA review vouchers.

Journal article The New England journal of medicine · February 2009 Full text Cite

Herding versus Hotelling: Market entry with costly information

Journal article Journal of Economics and Management Strategy · September 1, 2008 Why do businesses such as fast-food restaurants, coffee shops, and hotels cluster? In the classic analysis of Hotelling, firms cluster to attract consumers who have travel costs. We present an alternative model where firms cluster because one firm is free ... Full text Cite

International price comparisons for novel and follow-on drugs.

Journal article Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · November 2007 Full text Cite

Would greater transparency and uniformity of health care prices benefit poor patients?

Journal article Health affairs (Project Hope) · September 2007 President Bush, the World Health Organization, and leading scholars have called for greater price transparency in health care. Prices are transparent when the buyer knows his or her price or knows prices paid by others, in advance. Transparent prices infor ... Full text Cite

Entry and competition in generic biologics

Journal article Managerial and Decision Economics · June 1, 2007 Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In contrast with pharmaceuticals, which ... Full text Open Access Cite

Developing drugs for developing countries.

Journal article Health Aff (Millwood) · 2006 Featured Publication Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a ... Full text Open Access Link to item Cite

Spending on postapproval drug safety.

Journal article Health Aff (Millwood) · 2006 Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding safety efforts. Mean spending on ... Full text Open Access Link to item Cite

Postapproval drug safety: The authors respond [8]

Journal article Health Affairs · January 1, 2006 Full text Cite

Impact of Medicaid preferred drug lists on therapeutic adherence.

Journal article PharmacoEconomics · January 2006 ObjectiveTo estimate rates of non-adherence for statins following implementation of a preferred drug list (PDL).Study designA retrospective cohort study.MethodsA difference-in-difference-in-difference approach was used to estimat ... Full text Cite

Price differentiation and transparency in the global pharmaceutical marketplace.

Journal article PharmacoEconomics · January 2005 Pharmaceutical manufacturers have increased the availability of their products and sometimes increased their own financial returns by charging lower prices outside of the US and by discounting to lower-income patients in the US. Examples include discounted ... Full text Cite

Differential pricing of pharmaceuticals in the internet age.

Journal article The Journal of ambulatory care management · July 2004 The Internet provides healthcare consumers with more information about available prices and provides pharmaceutical manufacturers with more information about consumers' willingness to pay. The former effect tends to undermine price differences while the la ... Full text Cite

The cost of inefficiency in US hospitals, 1985-1997.

Journal article J Health Care Finance · 2003 We conducted a descriptive analysis of data from the Hospital Cost Report Information System from 1985 through 1997 on nonfederal, short-stay hospitals in the United States with 12-month reporting periods and valid data for the primary outcomes. The main o ... Link to item Cite